The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

BACKGROUND: BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematological toxicity (e.g. profound and prolonged cytopenias) repr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rejeski, Kai, Hansen, Doris K., Bansal, Radhika, Sesques, Pierre, Ailawadhi, Sikander, Logue, Jennifer M., Bräunlein, Eva, Cordas dos Santos, David M., Freeman, Ciara L., Alsina, Melissa, Theurich, Sebastian, Wang, Yucai, Krackhardt, Angela M., Locke, Frederick L., Bachy, Emmanuel, Jain, Michael D., Lin, Yi, Subklewe, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391746/
https://www.ncbi.nlm.nih.gov/pubmed/37525244
http://dx.doi.org/10.1186/s13045-023-01465-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391746/
https://www.ncbi.nlm.nih.gov/pubmed/37525244
http://dx.doi.org/10.1186/s13045-023-01465-x

Ejemplares similares